Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the...

Area of Science:

• Cardiology
• Interventional Cardiology
• Emergency Medicine

Background:

• Community hospitals without cardiac catheterization facilities offer limited reperfusion options for acute myocardial infarction (AMI).
• Current strategies include fibrinolysis with observation, transfer for primary percutaneous coronary intervention (PCI), or facilitated PCI.
• Facilitated PCI involves initial fibrinolysis and/or glycoprotein IIb/IIIa inhibitors followed by transfer for angiography and PCI.

Purpose of the Study:

• To systematically analyze trials on reperfusion therapy in AMI.
• To compare the efficacy of facilitated PCI with transfer-only or fibrinolysis-only strategies.
• To derive insights on the optimal timing and approach for reperfusion therapy based on symptom duration.

Main Methods:

• Systematic analysis of randomized and non-randomized trials.
• Review of the pathophysiology of reperfusion in AMI.
• Development of a hypothetical curve relating symptom duration to mortality reduction and myocardial salvage.

Main Results:

• Reperfusion benefit is striking within the first 2-3 hours of symptom onset, with time to treatment being critical.
• Facilitated PCI may offer substantial improvement in myocardial salvage and mortality for patients presenting 2-3 hours after symptom onset.
• For late presenters, facilitated PCI may not provide significant mortality benefit due to bleeding risks, while for very early presenters, fibrinolysis alone yields excellent outcomes.

Conclusions:

• The optimal reperfusion strategy for AMI depends critically on the timing of patient presentation.
• Facilitated PCI shows promise for patients presenting within the 2-3 hour window, potentially improving outcomes compared to other strategies.
• Further evidence from ongoing trials is needed to definitively establish the role of facilitated PCI in AMI management.